Partner Jordan Weiss proposes changes that sell-side lawyers should consider to head off a purchase price adjustment and level the post-close playing field between the buyer and the seller for M&A contracts.
Read the full article.
Related Content
- NewslettersOctober 17, 2025 – October 30, 2025
California Air Resources Board Posts Draft Scope 1 and 2 GHG Reporting Template
- NewslettersOctober 3, 2025 - October 16, 2025
SEC Chairman Vows to Make IPOs Great Again
- Hospitality & Leisure Trend WatchOctober 14, 2025
M&A Activity Continues to Escalate in the Global Hotel Operator Sector
- NewslettersSeptember 25, 2025 – October 10, 2025
OCC Issues Guidance and Proposed Rules to Reduce Regulatory Burdens on Depository Institutions
- NewslettersSeptember 19, 2025 – October 2, 2025
SEC Guidance on Operations During the U.S. Federal Government Shutdown
- AlertSeptember 30, 2025
Goodwin Antitrust & Regulatory Shorts: 10 Insights for Understanding and Managing Risk in Below-Threshold M&A
- NewslettersSeptember 12, 2025 – September 25, 2025
Treasury Seeks Public Comment on Implementation of the GENIUS Act
- NewslettersSeptember 1, 2025 - September 18, 2025
SEC Publishes Spring 2025 Regulatory (and Deregulatory) Agenda
- Press ReleaseNovember 14, 2025
Goodwin Advises SixPeaks Bio on Acquisition by AstraZeneca for Up to $300 Million
- Press Release10 November 2025
Vidi Capital Acquires the group CIL11
- Press ReleaseNovember 6, 2025
Bumble Enters into Agreement to Terminate Tax Receivable Agreement for $186 Million
- Awards and RankingsNovember 6, 2025
Best Law Firms 2026 Names Goodwin ERISA Litigation Law Firm of the Year and Recognizes 50 Practice Areas
- EventsOctober 28, 2025
Luncheon with Goodwin at Money 20/20
- Press ReleaseOctober 28, 2025
MeridianLink Completes its Acquisition by Centerbridge for $2.0 Billion
- In the PressOctober 27, 2025
Artificial Intelligence Funding Rounds Dominate as Valuations Keep Traditional M&A Buyers at Bay – Dealspeak North America (Mergermarket)
- Press ReleaseOctober 23, 2025
Goodwin Advises ImCheck Therapeutics on Acquisition by Ipsen for Up to €1 Billion